5470-11-1Relevant articles and documents
Joint production technology of hydroxylamine, hydroxylammonium salt and cyclohexanone-oxime
-
Paragraph 0015; 0030; 0031, (2017/09/26)
The invention discloses a joint production technology of hydroxylamine, hydroxylammonium salt and cyclohexanone-oxime. The material comprises the steps that reaction liquid obtained by raw materials through an ammoximation reaction and a hydrooximation reaction is extracted and separated to obtain an organic phase, the organic phase is prepared into product cyclohexanone-oxime, or part of the organic phase and part of product cyclohexanone-oxime are adopted as raw materials for an oxime hydrolysis reaction to be hydrolyzed, the organic phase in hydrolysis liquid is circulated to return to a oximation reactor, part of an inorganic phase in the hydrolysis liquid is adopted as a raw material to be circulated to return to a hydroxylamine oximation reactor, and the other part of the inorganic phase is prepared into a hydroxylamine aqueous solution and hydroxylammonium salt. The joint production technology of hydroxylamine, hydroxylammonium salt and cyclohexanone-oxime is simple in procedure, the requirement of the ammoximation reaction for the purity of the raw material cyclohexanone and the catalyst performance is lowered, a high quality cyclohexanone-oxime product without cyclohexanone is obtained, the simplification of the downstream caprolactam technology and the improvement of the product quality are benefited, and the hydroxylamine and hydroxylammonium salt product which have high additional value are obtained simultaneously.
MAGNETIC NANOSTRUCTURES AS THERANOSTIC AGENTS
-
, (2012/12/14)
The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.
Metalloprotease inhibitors
-
, (2008/06/13)
Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.
Composition for the treatment of damaged tissue
-
, (2008/06/13)
A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
-
, (2008/06/13)
The invention concerns compounds selected among the group consisting of (i) compounds of formula (I) wherein: Het1 represents a nitrogenous heterocycle with 5 apices, in particular imidazole, pyrazole, or triazole; Het2 represents a nitrogenous heterocycle with 4, 5 or 6 apices, selected among the heterocycles: (II) wherein R1and R2are defined as mentioned in the description; and (ii) their additive salts. The invention also concerns the method for preparing said compounds and their use in therapy, in particular for treating pathologies involving bradykinine.
Substituted isoxazolylthiophene compounds
-
, (2008/06/13)
This invention provides a substituted isoxazolylthiophene compound represented by the formula wherein R1and R2individually represent an alkyl group of 1-5 carbon atoms, R3represents a cyano group or a group CONR5R6(in which R5and R6individually represent a hydrogen atom or an alkyl group of 1-10 carbon atoms), R4represents an alkyl group of 1-5 carbon atoms or a phenyl group, and n is an integer of 0-2, or a salt thereof. The compounds of the invention are useful for the treatment or prevention of various bone diseases or nerve diseases, because they specifically enhance the action of the cell differentiation induction factors found in a living body.
Pyridinium compounds
-
, (2008/06/13)
Methods for using novel quaternary pyridinium compounds in inhibiting acetylcholinesterase in mammals, specifically using the quaternary pyridinium compounds in the prophylaxis and treatment of organophosphate poisoning and mammalian dementia by mimicking or opposing the actions of the natural neurotransmitter acetylcholine.
Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
-
, (2008/06/13)
This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection. A representative compound of the invention is the compound of formula: STR1 wherein R22 and R23 are allyl.
Process for the preparation of O-substituted hydroxylammonium salts
-
, (2008/06/13)
Preparation of O-substituted hydroxylammonium salts I (L=halogen, hydrogensulfate; X=H, alkyl; R1 =unsubst. or subst. phenyl, thienyl, furanyl, pyrrolyl or --CR2 =CR3 R4 ; R2, R3, R4 =H, halogen or alkyl) by reaction of an acetone oxime O-allyl or --O--benzyl ether II STR1 with water and a mineral acid H--L with continuous removal of the acetone formed in this process, by carrying out the hydrolysis batchwise at 0°-50° C. and under a pressure of 10-500 mbar is described. The O-substituted hydroxylammonium salts I are intermediates for plant protection agents and pharmaceuticals.
PROTEASE-BINDING COMPOUNDS AND METHODS OF USE
-
, (2008/06/13)
Non-peptide, protease-binding compounds are described as useful in the detection, labelling, and inhibition of retroviral proteases. Aryl piperidinyl derivatives and other compounds related in structure have been found to be HIV-1 and HIV-2 protease-binding compounds.
